Connect with us on the social channels
Press Releases
DCprime Receives US FDA Orphan Drug Designation for DCP-001 in Acute Myeloid Leukemia
Leiden, The Netherlands, December 05, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCP-001 for the treatment of acute myeloid leukemia (AML). DCP-001 is a cell-based vaccine addressing blood cancers with
DCprime to Present Long-term Follow-up and Survival Data for Lead Relapse Vaccine Candidate DCP-001 in High-Risk AML and MDS Patients
Presentation at ASH Annual Meeting Shows Potential to Prolong Relapse-Free Survival and Overall Survival Using an Allogeneic Cell-based Vaccine in the Post-Remission Setting Leiden, The Netherlands, November 13, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of updated clinical results for its lead product
DCprime Presents Preclinical Data on Novel Vaccination Concept Using the DCOne® Cell Line in Solid Tumour Models
Presentation at SITC Shows Potential to Flag Solid Tumours as a Target for the Immune System to Attack Using the Company’s DCOne® Cell Vaccine Loaded with a Foreign Antigen Leiden, The Netherlands, November 6, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of preclinical
DCprime Initiates Research Collaboration with the University Medical Center of Groningen on Relapse Vaccine Approach for Ovarian Cancer
Leiden, The Netherlands, September 10, 2019 – DCprime, the front-runner in the field of relapse vaccines, today announced the initiation of a research collaboration with the Department of Obstetrics and Gynecology at the University Medical Center of Groningen (UMCG) lead by Professor Hans Nijman MD PhD. The purpose of the
DCprime Presents Comprehensive Preclinical Results Supporting Lead Clinical Candidate DCP-001
Leiden, The Netherlands, May 14, 2019 – DCprime, the front-runner in the field of relapse vaccines, today announced presentations of additional preclinical data sets for its lead program, DCP-001, at the 7th CCBIO Annual Symposium and the 2019 CIMT Annual Meeting. The data supports key product characteristics and sheds additional
DCprime Strengthens Supervisory Board with the Additions of Andrea van Elsas and Hans Preusting
Leiden, The Netherlands, April 25, 2019 – DCprime, the front-runner in the field of relapse vaccines, today announced the appointment of two highly-experienced industry veterans, Andrea van Elsas, Ph.D. and Hans Preusting, Ph.D., M.B.A, to its Supervisory Board. The newest members complement the existing Board, with Dharminder Chahal remaining Chairman
DCprime and Radboudumc to collaborate
Leiden, The Netherlands and Nijmegen, The Netherlands, March 2019– DCprime and Radboudumc announce that they will collaborate as part of a public-private consortium supported by The Dutch Top Sector Life Sciences and Health, represented by Stichting Life Sciences Health – TKI, also acting under its trade name Health~Holland, under the